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ABSTRACT-Objectives. The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) 
was shown to improve the differentiation between prostate carcinoma and benign conditions in selected se- 
ries of patients. In this study the F/T ratio was analyzed for its ability to improve the specificity of total serum 
PSA, digital rectal examination (DRE), and transrectal ultrasonography (TRUS) for the detection of prostate 
cancer in an unselected screening population of men identified in the Rotterdam population. 
Methods. In 1726 men between 55 and 76 years old, 67 prostate carcinomas were detected by DRE, 
TRUS, and total serum PSA (Abbott IMx, Hybritech Tandem E). The DELFIA ProStatus PSA EQM and ProSta- 
tus PSA Free/Total assays (Wallac) were applied in retrospect to determine total and free serum PSA. Age, to- 
tal prostate and inner zone volumes were taken into consideration. 
Results. Sixty-seven carcinomas were detected, two by TRUS and three by DRE alone. Total serum PSA was 
the most important single predictor of prostate cancer, followed by DRE. The F/T ratio increased the speci- 
ficity of total serum PSA in the PSA range between 4.0 and 10.0 ng/mL. However, this improved specificity 
was not significant, nor for gland volumes restricted to 50 mL or less. 
Conclusions. The combination of total serum PSA and DRE remains the standard for detection of prostate 
carcinoma in a screening population. Their specificity may be improved minimally by the F/T ratio, but not sig- 
nificantly in a sample of 1726 screened men. The threshold of the F/T ratio, and the optimal PSA range for 
its application, remains to be assessed prospectively. UROLOGYe 46: 773-778, 1995. 
S creening for prostate cancer (PC) has been per- formed from June 1994 onward in the Rotter- 
dam area as part of the European Randomised Study 
of Screening for Prostate Carcinoma (ERSPC) to 
study the usefulness of early detection in the gen- 
eral population. 
Selection of candidates for prostate biopsy is 
complicated by the fact that all screening modal- 
ities lack sufficient specificity. This results in a 
high ratio between the number of biopsies and 
the number of detected carcinomas. In most 
screening studies, overall about five biopsies are 
needed to detect one carcinoma.lm5 
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Several additional parameters, such as prostate 
volume and age, have been used in an attempt 
to reduce this unfavorable ratio, without loss of 
sensitivity.6,7 
Prostate-specific antigen (PSA) can be found 
in serum in a free form or may be bound to 
various serum proteins, predominantly alphai- 
antichymotrypsin (ACT).8,9 The detection of 
PSA depends on the identification of antigenic 
epitopes on the PSA molecule by labeled anti- 
bodies. Some of these epitopes may be (steri- 
tally) obscured by serum proteins, predomi- 
nantly by ACT. lo This introduces the possibility 
of discriminating between free (F) and com- 
plexed PSA, and of calculating the ratio between 
free and total PSA (F/T ratio). In selected groups 
the ratio between free and complexed PSA im- 
proves the differentiation between prostate car- 
cinoma and benign conditions.“-‘3 
The concept of F/T ratio offers a new parameter 
for the early detection of PC in addition to total 
serum PSA, digital rectal examination (DRE), and 
transrectal ultrasonography (TRUS). The question 
is raised whether the F/T ratio can increase the 
specificity of existing tests or their combinations in 
order to reduce the number of negative biopsies, or 
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even replace a number of them to make screening 
less invasive and more cost-effective. To assess the 
value of the F/T ratio, it should be compared to 
other parameters, such as age, total prostate volume 
and transition zone volume, total PSA, DRE, and le- 
sions seen by TRUS, which have been used to dif- 
ferentiate between normal and pathologic prostates 
in screening populations. In men within the PSA 
range between 4.0 and 10.0 ng/mL with glands 
smaller than 50 mL, the F/T ratio has been reported 
to increase the specificity to detect PC.14 The vari- 
ous parameters should be analyzed in a representa- 
tive sample of the male population, independent of 
the PSA level. The best estimate of the incidence of 
PC in the general population would be obtained by 
submitting all participants to sextant prostate biop- 
sies. However, this is not feasible. Assessment of 
screening modalities, therefore, will always be bi- 
ased by the method of sampling and by the method 
of PC detection in the population studied. 
MATERIAL AND METHODS 
MATERIAL 
Serum samples, which had been stored at -7O”C, were 
used to determine total and free PSA by two DELFIA second 
generation PSA assays. 
The DELFIA ProStatus PSA Free/Total assay provides si- 
multaneous dual label measurement of free and total PSA by 
using time-resolved fluorometry of europium (free PSA) and 
samarium chelates (total PSA). The ProStatus PSA EQM pro- 
vides a highly sensitive single label (europium) assay of to- 
tal PSA. Both assays measure total PSA with the same reagent 
combination to give equimolar detection of PSA in free and 
complexed form. The detection limits for the dual label as- 
say are less than 0.01 ng/mL, and less than 0.1 ng/mL for free 
and total PSA, respectively, and less than 0.01 ng/mL for the 
single label total PSA assay. Regarding the imprecision of 
both ProStatus assays, we found coefficients of variation be- 
tween 7.2% (at a serum concentration of 0.7 ng/mL) and 
4.3% (at a serum concentration of 70.7 ng/mL) for total PSA, 
and between 10.3% (at a serum concentration of 0.17 ng/mL) 
for free PSA and 3.7% (at a serum concentration of 35.5 ng/mL) 
during 22 days, with six control samples supplied by the 
manufacturer. 
The correlation coefficient (r) between the ProStatus as- 
says and both the Abbott IMx and the Hybritech Tandem E 
assays has shown to be better than 0.97 for men with and 
men without PC.15,16 
METHODS 
Two sample collections of men originating from the Rot- 
terdam community were combined for this study: 903 par- 
ticipants of the ERSPC, and 823 men of the Rotterdam fea- 
sibility study for screening prostate carcinoma.17 All men 
aged 55 to 77 years had been randomized for total serum 
PSA determination (Hybritech Tandem E for the ERSPC par- 
ticipants, Abbott IMx for the feasibility study), DRE, and 
TRUS. Blood sampling was done prior to further testing, and 
DRE was performed before TRUS by one of five well-trained 
urology residents without knowledge of the PSA values. An 
1846 Bruel and Kjaer 7.0 MHz biplanar ultrasound probe 
was used for diagnostic ultrasonography, and planimetric 
volumetry of the prostate gland and its inner zone.18 Ultra- 
sound-guided sextant prostatic biopsies were taken in case of 
an elevated PSA more than 4.0 ng/mL and/or a suspect DRE, 
and, in case of hypoechoic lesions seen by TRUS, biopsies of 
these lesions were taken in addition to sextant biopsies. All 
men with a negative biopsy, and those in whom no biopsy 
was taken, were considered free of PC. 
The biopsy results were used to assess the capability of the 
F/T ratio in combination with the total PSA to detect prostate 
carcinoma, as biopsy illustrated the definite histologic status 
of the individual. 
STATISTICS 
Continuous parameters were compared by means of the 
Mann-Whitney U test (a two-sided 0.05 level of significance 
was used). Linear univariate regression analysis of continu- 
ous parameters, such as total PSA, free PSA, total prostate 
volume, volume of the inner zone, and age, was used to ex- 
press the correlation between factors. 
Predictors for a positive biopsy result were estimated as a 
function of these parameters, and of binary parameters, such 
as DRE and TRUS, by means of logistic regression analysis. 
Logistic regression analysis was chosen as the distribution of 
the values of various parameters was not Gaussian. It was re- 
alized that several parameters may show significant correla- 
tion to each other. For all men who had biopsies, these pa- 
rameters were used as input in a backward deletion logistic 
regression analysis. The output of this procedure is a pre- 
dictor that specifies the chance on a positive biopsy result as 
a function of the variables most relevant to this end. All vari- 
ables with insignificant Wald statistics are deleted.lg The rel- 
ative intrinsic discriminatory potential of these predictors 
was assessed by comparing receiver operating characteristic 
(ROC) curves, in which each point of the curve fits a com- 
bination of a level of sensitivity with its specificity.20 For the 
predictor with the best properties (this is the largest area un- 
der the ROC curve), the predictive value was determined. 
In the subgroup of men in the PSA range between 4.0 and 
10.0 ng/mL, sensitivity and specificity of the F/T ratio to pre- 
dict prostate carcinoma were calculated for all prostate gland 
volumes and for those smaller than 50 mL. 
RESULTS 
General characteristics of all men are shown in 
Table I. In 1726 men 67 cancers were histologi- 
cally diagnosed by 308 sextant prostate biopsies. 
Planimetric volumetry was available in 1565 be- 
nign and 64 malignant prostates. Table II shows 
the ratio between the biopsies taken and the can- 
cers detected (the Bx/PC ratio) for each of the 
screening modalities, or the four possible combi- 
nations. The Bx/PC illustrates the number of biop- 
sies needed to detect one cancer and is the recip- 
rocal of the positive predictive value of that 
screening modality A suspicious TRUS alone 
showed the largest number of biopsies needed to 
detect one carcinoma, while the combination of a 
suspicious TRUS, an abnormal DRE, and a PSA 
value of 4.0 ng/mL or more was the most efficient 
in detecting PC. 
The values of F/T ratio measured by the ProSta- 
tus Free/Total PSA assay in relation to men with 
and without cancer is illustrated in Figure 1 by 
Box Whisker plots. The box includes the results 
of 50% of the participants, with the median value 
plotted inside. The notch represents the 95% con- 
fidence interval of the median. and the middle 
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TABLE 1. Age, prostatic volumes, and PSA values of 1659 apparently benign prostates 
and 67 with prostate cancer 
Benign Prostate Cancer 
Number Median Range Number Median Range 
Age WI 1659 64 54-77 67 66.8 55.6-76.2 
Total prostate volume (mL) 1565 31 8-204 64 33 16-105 
Total PSA (ng/mL) 
DELFIA ProStatus EQM 1659 1.3 o-35 67 7.2 0.4-165 
DELFIA ProStatus Free/Total 1659 1.2 O-30 67 7.6 0.5-150 
Free PSA (ng/mLl 1659 0.33 0.01-8.4 67 0.89 0.15-l 5.6 
DELFlkP~oSt&us Free/Total Ratio 1659 0.28 0.05-1.0 67 0.12 0.04-0.47 
0.01 I I NO” ca”cer (N-r&s) Cancer (N - 87, 
FIGURE 1. The PSA free to total (F/r) ratio in 1659 
benign and 67 prostate cancer patients, Box Whisker 
plots. P c 0.05. 
vertical line the 90% interval of all values. The 
median F/T ratio for 1726 benign participants was 
0.28, which significantly differed from the F/T ra- 
tio of 0.12 of 67 men with a carcinoma. 
In Figure 2 the relationship between F/T ratio 
and the total PSA for 308 men who underwent a 
prostate biopsy is depicted. It can be seen that the 
distribution of detected cancers overlaps that of 
nonmalignancies, especially in the PSA range be- 
tween 4.0 and 10.0 ng/mL. 
4 
I 
TABLE II. Ratio between the biopsies taken 
and the carcinomas detected (the Bx/PC) for 
each of the screening modalities, or the four 
possible combinations 
No. biopsies No. PC BxlPC 
TRUS alone 53 2 26.5 
DRE alone 29 3 9.7 
PSA alone 126 22 5.7 
TRUS + DRE 48 7 6.9 
TRUS + PSA 11 4 2.8 
DRE + PSA 11 6 1.8 
TRUS + DRE + PSA 30 23 1.3 
Total 308 67 4.6 
KEY: Bx = biopsy; DRE = digital rectal ucamination; PC = prostate cancer; TRUS = 
tramrectal ultrasonography. 
The relative effectiveness of the diagnostic tests 
was illustrated in the ROC curves of Figure 3. These 
ROC curves show that, with a standard error of the 
areas of 0.03, the addition of DRE improved the de- 
tection of prostate carcinoma by total serum PSA 
significantly Addition of free PSA to the combina- 
tion of PSA and DRE improved detectability by 1 
308 Biopsies 
. 
67 Cancers 
FIGURE 2. The relationship be- 
tween free to total (F/T) ratio 
and the total PSA for 308 men 
who underwent a prostate 
biopsy; 67 cancers are indi- 
cated. CA = carcinoma, NCA 
= no carcinoma. 
1 10 100 200 
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Total PSA, ProStatus PSAF/T [ng/mL] 
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FlGLJRE 3. The relative effec- 
tiveness of diagnostics iNus- 
trated in receiver operating 
characteristic curves of 287 
men who underwent prostate 
biopsies. Standard error of the 
areas = 0.03, DRE = digital 
rectal examination; Z = zone. 
FIGURE 4. The relative effec- 
tiveness of diagnostics illustrated 
in receiver operating character- 
istic curves of 140 men who un- 
derwent prostate biopsies in the 
total serum PSA range between 
4.0 and 10.0 ng/mL. Standard 
error of the areas = 0.05. F/T = 
free to total. 
1 - specificity 
TABLE 111, Results of univariate regression analysis: P -e 0.0 1 
Volume 
Correlation 
Benign (n = 1542) 
Log PSA 
Log free PSA 
Voume total gland 
Volume inner zone 
Prostate cancer (n = 61) 
Log PSA 
Log free PSA 
Volume total gland 
Volume inner zone 
Log PSA Log Free PSA Total Gland Inner Zone Age 
0.87 0.54 0.41 0.16 
0.62 0.45 0.22 
0.74 0.23 
0.22 
0.81 0.1 1 0.08 0.12 
0.46 0.32 0.31 
0.70 0.26 
0.24 
standard error. The best predictor of a positive 
biopsy was obtained by the combination of total 
PSA, DRE, inner zone volume, and free PSA. 
For the range of total PSA between 4.0 and 10.0 
ng/mL, including 140 prostate biopsies and 33 
PCs, the ROC curves of total serum PSA and of 
the F/T ratio were constructed to illustrate their 
relative potential to predict a positive biopsy (Fig. 
4). The standard error of the areas under the curve 
was 0.05. No significant difference between the 
curves was obtained. 
In TabIe III, the results of the linear univariate 
regression analysis are shown for 61 men with 
carcinoma, and 1542 without carcinoma. All cor- 
relations were significant. A high correlation ex- 
isted between total and free PSA. Volumetric pa- 
rameters correlated slightly better with free PSA 
compared to total serum PSA. For men with 
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TABLE IV. Results of logistic regression 
analysis of independent parameters for 
predicting a positive biopsy in 308 men, first 
step in backward deletion procedure 
Variable B SE Wald Significance 
Log PSA 5.84 0.98 35.12 0.00 
Log free PSA -2.32 1.15 4.03 0.04 
DRE -0.93 0.24 14.97 0.00 
Volume total -0.0 1 0.01 0.58 0.44 
Volume inner -0.03 0.02 3.71 0.05 
Age 0.04 0.04 1.06 0.30 
TRUS -0.18 0.22 0.63 0.42 
KEY: B = predictor for a positive biopsy; SE = standard error of the predictor; 
Wald statistic = square of the ratio of the predictor to its standard error; 
sign$cance = Wald statistic, threshold 0.05. 
prostate cancer, the correlation between volumet- 
ric parameters and PSA was less compared to men 
without a carcinoma. Age was uniformly mildly 
correlated to all other parameters. 
In Table IV, the results of logistic regression 
analysis of the parameters for predicting a posi- 
tive biopsy in 308 men are shown. Total serum 
PSA was the best single predictor for prostate car- 
cinoma, followed by DRE. Free PSA and the ul- 
trasonic volume of the inner zone of the prostate 
were just significant as predictors. Age was the 
first parameter deleted in the backward stepwise 
elimination procedure, followed by total prostate 
volume and TRUS. 
Table V shows the calculation of the sensitivity 
and specificity of the F/T ratio for men in the PSA 
range between 4.0 and 10.0 ng/mL. In Table V(A), 
all 140 men are included; in Table V(B), the 81 
men with a planimetric prostate gland volume of 
less than 50 mL are included. The standard er- 
rors were calculated to illustrate the confidence 
ranges (k 2 SE) of the chosen sensitivity and speci- 
ficity levels. For an F/T ratio cutoff value of 0.20, 
a sensitivity level of 82% (95% confidence range 
of 64% to 100%) and a specificity of 51% (range, 
43% to 59%) were found. In the volume-restricted 
group, the sensitivity at the same cutoff value was 
approximately 90% (Table VB), and the specificity 
was 49% (range, 37% to 61%). The small num- 
bers (22 cancers in 81 men, or 5% of the studied 
population) introduced wide confidence ranges. 
COMMENT 
For the detection of PC currently, the combina- 
tion of serum PSA, DRE, and TRUS is available. 
Detection rates in community-based populations 
vary between 2% and 5%. In this study the detec- 
tion rate was 3.3%. A combination of total serum 
PSA, DRE, and TRUS as indicators for biopsy led 
to a subset of men in whom I.3 sextant prostate 
biopsies were needed to detect one carcinoma. 
The mean Bx/PC ratio was 4.6. These ratios cor- 
respond very well to those found by Catalona et 
~1.~ in a screening study of 6630 men evaluated by 
PSA and DRE. In this study it was also found that 
the Bx/PC ratio is relatively constant across age. 
Further clarifying information on the optimal use 
of the available screening tests will, it is hoped, be 
an early result of the ERSPC. 
Serum PSA is the best single screening modal- 
ity for prostate carcinoma available, as shown in 
Table II. Logistic regression analysis could illus- 
trate the value of various parameters, which were 
no indicators for sextant biopsy in this study 
(Table IV). Due to the high correlation between 
total serum and free PSA, much of the influence 
of free PSA as a predictor was reduced by total 
serum PSA. Due to the higher correlation between 
total or free PSA and the total gland volume, this 
volumetric parameter was replaced by the inner 
zone volume in the backward elimination proce- 
dure. A combination of the modalities of serum 
PSA and DRE, with others, such as free PSA or 
the volume of the inner zone of the prostate, may 
add to the specificity and sensitivity of the detec- 
tion, as illustrated by an increasing area under the 
ROC curve (Fig. 3). DRE increased the area of to- 
tal serum PSA by 2 SE, whereas the combination 
of DRE and free PSA increased the area by 3 SE. 
It is suggestive, although not statistically signifi- 
cant, that the application of the F/T ratio in addi- 
tion to total serum PSA in combination with DRE 
TABLE V. Sensitivitu and soecificitu of the free to total ratio to detect prostate cancer 
Sensitivity SE Specificity SE Free to Total Ratio Cutoff 
100 
91 
82 
71 
100 
91 
82 
73 
A:PSA4tolOng/mL(n = 140,PC = 33) 
0 
2 19 2 
9 51 4 
8 68 4 
B: PSA 4 to 10 ng/mL, gland volume < 50 mL (n = 81, PC = 22) 
39 6 
6 49 6 
9 74 6 
10 82 5 
0.41 
0.28 
0.20 
0.17 
0.2 1 
0.19 
0.14 
0.12 
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for screening for PC is useful. No optimal analy- 
sis could be performed in the total PSA range be- 
low 4.0 ng/mL, as biopsies were taken only on the 
indication of TRUS or DRE. For the total PSA 
range between 4.0 and 10.0 ng/mL, however, no 
significant difference between the ROC curves 
was obtained in this study. 
The use of TRUS for prostate volumetry and le- 
sion detection in screening for prostate cancer 
does not appear to be cost-effective. Ultrasonic 
volume of the inner zone (as a representation of 
the prostatic hyperplasia), only marginally adds 
to the prediction of a positive biopsy Calculation 
of sensitivity and specificity in glands restricted to 
a volume of 50 mL or less in the gray PSA range 
between 4.0 and 10.0 ng/mL did not reveal statis- 
tically significant improvement in specificity com- 
pared to the whole group in this PSA range. Le- 
sion detection by TRUS did not have significant 
predictive value in the logistic regression analysis. 
This means that the two carcinomas detected by 
TRUS (Table II) could have been detected by use 
of the free PSA or the inner zone volume. The lo- 
gistic regression does not illustrate the number of 
biopsies needed for the detection of those two 
carcinomas, but from Table II it can be seen that 
26.5 biopsies per cancer found were needed to de- 
termine histologically the cause of those hypo- 
echogenic lesions. 
CONCLUSIONS 
The combination of total serum PSA and DRE 
remains the standard for detection of prostate car- 
cinoma in a screening population. Their speci- 
ficity may be improved minimally by the F/T ra- 
tio, and statistical significance might be reached 
in a population larger than 1726 men. The thresh- 
old of the F/T ratio, and the PSA range for its ap- 
plication, remains to be assessed prospectively. 
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